Shuangshuang Song1,2, Leiming Wang3, Hongwei Yang4, Yongzhi Shan5, Ye Cheng5, Lixin Xu5, Chengyan Dong6, Guoguang Zhao5, Jie Lu7,8,9. 1. Department of Radiology, Xuanwu Hospital, Capital Medical University, No. 45 Changchun Street, Xicheng District, Beijing, 100053, China. 2. Beijing Key Laboratory of Magnetic Resonance Imaging and Brain Informatics, Beijing, China. 3. Department of Pathology, Xuanwu Hospital, Capital Medical University, Beijing, China. 4. Department of Nuclear Medicine, Xuanwu Hospital, Capital Medical University, Beijing, China. 5. Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, China. 6. GE Healthcare, Beijing, China. 7. Department of Radiology, Xuanwu Hospital, Capital Medical University, No. 45 Changchun Street, Xicheng District, Beijing, 100053, China. imaginglu@hotmail.com. 8. Beijing Key Laboratory of Magnetic Resonance Imaging and Brain Informatics, Beijing, China. imaginglu@hotmail.com. 9. Department of Nuclear Medicine, Xuanwu Hospital, Capital Medical University, Beijing, China. imaginglu@hotmail.com.
Abstract
OBJECTIVES: To investigate the predictive value of static O-(2-18F-fluoroethyl)-L-tyrosine positron emission tomography (18F-FET PET) and cerebral blood volume (CBV) for glioma grading and determining isocitrate dehydrogenase (IDH) mutation and 1p/19q codeletion status. METHODS: Fifty-two patients with newly diagnosed gliomas who underwent simultaneous 18F-FET PET and dynamic susceptibility contrast perfusion-weighted imaging (DSC-PWI) examinations on hybrid PET/MR were retrospectively enrolled. The mean and max tumor-to-brain ratio (TBR) and normalized CBV (nCBV) were calculated based on whole tumor volume segmentations with reference to PET/MR images. The predictive efficacy of FET PET and CBV in glioma according to the 2016 World Health Organization (WHO) classification was evaluated by receiver operating characteristic curve analyses with the area under the curve (AUC). RESULTS: TBRmean, TBRmax, nCBVmean, and nCBVmax differed between low- and high-grade gliomas, with the highest AUC of nCBVmean (0.920). TBRmax and nCBVmean showed significant differences between gliomas with and without IDH mutation (p = 0.032 and 0.010, respectively). Furthermore, TBRmean, TBRmax, and nCBVmean discriminated between IDH-wildtype glioblastomas and IDH-mutated astrocytomas (p = 0.049, 0.034 and 0.029, respectively). The combination of TBRmax and nCBVmean showed the best predictive performance (AUC, 0.903). Only nCBVmean differentiated IDH-mutated with 1p/19q codeletion oligodendrogliomas from IDH-wildtype glioblastomas (p < 0.001) (AUC, 0.829), but none of the parameters discriminated between oligodendrogliomas and astrocytomas. CONCLUSIONS: Both FET PET and DSC-PWI might be non-invasive predictors for glioma grades and IDH mutation status. FET PET combined with CBV could improve the differentiation of IDH-mutated astrocytomas and IDH-wildtype glioblastomas. However, FET PET and CBV might be limited for identifying oligodendrogliomas. KEY POINTS: • Static 18F-FET PET and DSC-PWI parameters differed between low- and high-grade gliomas, with the highest AUC of the mean value of normalized CBV. • Static 18F-FET PET and DSC-PWI parameters based on hybrid PET/MR showed predictive value in identifying glioma IDH mutation subtypes, which have gained importance for both determining the diagnosis and prognosis of gliomas according to the 2016 WHO classification. • Static 18F-FET PET and DSC-PWI parameters have limited potential in differentiating IDH-mutated with 1p/19q codeletion oligodendrogliomas from IDH-wildtype glioblastomas or IDH-mutated astrocytomas.
OBJECTIVES: To investigate the predictive value of static O-(2-18F-fluoroethyl)-L-tyrosine positron emission tomography (18F-FET PET) and cerebral blood volume (CBV) for glioma grading and determining isocitrate dehydrogenase (IDH) mutation and 1p/19q codeletion status. METHODS: Fifty-two patients with newly diagnosed gliomas who underwent simultaneous 18F-FET PET and dynamic susceptibility contrast perfusion-weighted imaging (DSC-PWI) examinations on hybrid PET/MR were retrospectively enrolled. The mean and max tumor-to-brain ratio (TBR) and normalized CBV (nCBV) were calculated based on whole tumor volume segmentations with reference to PET/MR images. The predictive efficacy of FET PET and CBV in glioma according to the 2016 World Health Organization (WHO) classification was evaluated by receiver operating characteristic curve analyses with the area under the curve (AUC). RESULTS: TBRmean, TBRmax, nCBVmean, and nCBVmax differed between low- and high-grade gliomas, with the highest AUC of nCBVmean (0.920). TBRmax and nCBVmean showed significant differences between gliomas with and without IDH mutation (p = 0.032 and 0.010, respectively). Furthermore, TBRmean, TBRmax, and nCBVmean discriminated between IDH-wildtype glioblastomas and IDH-mutated astrocytomas (p = 0.049, 0.034 and 0.029, respectively). The combination of TBRmax and nCBVmean showed the best predictive performance (AUC, 0.903). Only nCBVmean differentiated IDH-mutated with 1p/19q codeletion oligodendrogliomas from IDH-wildtype glioblastomas (p < 0.001) (AUC, 0.829), but none of the parameters discriminated between oligodendrogliomas and astrocytomas. CONCLUSIONS: Both FET PET and DSC-PWI might be non-invasive predictors for glioma grades and IDH mutation status. FET PET combined with CBV could improve the differentiation of IDH-mutated astrocytomas and IDH-wildtype glioblastomas. However, FET PET and CBV might be limited for identifying oligodendrogliomas. KEY POINTS: • Static 18F-FET PET and DSC-PWI parameters differed between low- and high-grade gliomas, with the highest AUC of the mean value of normalized CBV. • Static 18F-FET PET and DSC-PWI parameters based on hybrid PET/MR showed predictive value in identifying glioma IDH mutation subtypes, which have gained importance for both determining the diagnosis and prognosis of gliomas according to the 2016 WHO classification. • Static 18F-FET PET and DSC-PWI parameters have limited potential in differentiating IDH-mutated with 1p/19q codeletion oligodendrogliomas from IDH-wildtype glioblastomas or IDH-mutated astrocytomas.
Authors: Nathalie L Albert; Michael Weller; Bogdana Suchorska; Norbert Galldiks; Riccardo Soffietti; Michelle M Kim; Christian la Fougère; Whitney Pope; Ian Law; Javier Arbizu; Marc C Chamberlain; Michael Vogelbaum; Ben M Ellingson; Joerg C Tonn Journal: Neuro Oncol Date: 2016-04-21 Impact factor: 12.300
Authors: Zachary K Englander; Craig I Horenstein; Stephen G Bowden; Daniel S Chow; Marc L Otten; Angela Lignelli; Jeffrey N Bruce; Peter Canoll; Jack Grinband Journal: Radiology Date: 2018-01-24 Impact factor: 11.105
Authors: Jeanette E Eckel-Passow; Daniel H Lachance; Annette M Molinaro; Kyle M Walsh; Paul A Decker; Hugues Sicotte; Melike Pekmezci; Terri Rice; Matt L Kosel; Ivan V Smirnov; Gobinda Sarkar; Alissa A Caron; Thomas M Kollmeyer; Corinne E Praska; Anisha R Chada; Chandralekha Halder; Helen M Hansen; Lucie S McCoy; Paige M Bracci; Roxanne Marshall; Shichun Zheng; Gerald F Reis; Alexander R Pico; Brian P O'Neill; Jan C Buckner; Caterina Giannini; Jason T Huse; Arie Perry; Tarik Tihan; Mitchell S Berger; Susan M Chang; Michael D Prados; Joseph Wiemels; John K Wiencke; Margaret R Wrensch; Robert B Jenkins Journal: N Engl J Med Date: 2015-06-10 Impact factor: 176.079
Authors: Nanne K Kloosterhof; Linda B C Bralten; Hendrikus J Dubbink; Pim J French; Martin J van den Bent Journal: Lancet Oncol Date: 2010-07-07 Impact factor: 54.433
Authors: Martinus P G Broen; Marion Smits; Maarten M J Wijnenga; Hendrikus J Dubbink; Monique H M E Anten; Olaf E M G Schijns; Jan Beckervordersandforth; Alida A Postma; Martin J van den Bent Journal: Neuro Oncol Date: 2018-09-03 Impact factor: 13.029
Authors: Gilbert Hangel; Philipp Lazen; Sukrit Sharma; Barbara Hristoska; Cornelius Cadrien; Julia Furtner; Ivo Rausch; Alexandra Lipka; Eva Niess; Lukas Hingerl; Stanislav Motyka; Stephan Gruber; Bernhard Strasser; Barbara Kiesel; Matthias Preusser; Thomas Roetzer-Pejrimovsky; Adelheid Wöhrer; Wolfgang Bogner; Georg Widhalm; Karl Rössler; Tatjana Traub-Weidinger; Siegfried Trattnig Journal: Cancers (Basel) Date: 2022-04-26 Impact factor: 6.575
Authors: Vittorio Stumpo; Lelio Guida; Jacopo Bellomo; Christiaan Hendrik Bas Van Niftrik; Martina Sebök; Moncef Berhouma; Andrea Bink; Michael Weller; Zsolt Kulcsar; Luca Regli; Jorn Fierstra Journal: Cancers (Basel) Date: 2022-03-05 Impact factor: 6.639
Authors: Andreas Stadlbauer; Gertraud Heinz; Stefan Oberndorfer; Max Zimmermann; Thomas M Kinfe; Michael Buchfelder; Arnd Dörfler; Natalia Kremenevski; Franz Marhold Journal: Neuroradiology Date: 2021-06-11 Impact factor: 2.804
Authors: Lelio Guida; Vittorio Stumpo; Jacopo Bellomo; Christiaan Hendrik Bas van Niftrik; Martina Sebök; Moncef Berhouma; Andrea Bink; Michael Weller; Zsolt Kulcsar; Luca Regli; Jorn Fierstra Journal: Cancers (Basel) Date: 2022-03-10 Impact factor: 6.639